## **CUMULATIVE INDEX 1992**

## Volume 15

March PEDIATRIC PSYCHOPHARMACOLOGY, pages 1–282 June THE INTERFACE OF PSYCHIATRY AND NEUROLOGY,

pages 283-528

September CLINICAL FORENSIC PSYCHIATRY, pages 529-742

December OBSESSIONAL DISORDERS, pages 743-956

Note: Page numbers of issue and article titles are in boldface type

Abilities, premorbid, estimation of, 285-

seizures and, age at onset of, 388 duration of disorder, 389 etiology of, 387–388

frequency of, 390 type of, 386

Achromatopsia, stroke and, 420–421

Acquired immunodeficiency syndrome (AIDS). See HIV encephalopathy.

Acquittees, insanity, schizophrenic, 591–603

ADHD. See Attention deficit hyperactivity disorder.

Adjustment, seizures and, age at onset of, 388–389

duration of disorder, 389-390

etiology of, 388 frequency of, 390

type of, 386-387

Adolescents. See also Children; specific adolescent disorders.

pharmacologic treatment of. See also specific drug or type of drug, for anxiety disorders, 41–62

for depression, 29-37

for obsessive compulsive disorder, 87–103

sleep physiology and development in, 162–164. See also *Sleep disorders*. stimulant efficacy in, 204–205, 206

trichotillomania in, 780–785. See also *Trichotillomania*.

early onset versus, 787-788

Affective disorders, major, forensic

psychiatry and, 569–573 Age. See also Senescence.

at epilepsy onset, neuropsychological functioning and, 388–389

head injuries and, neuropsychiatric sequelae of, 406–407

at obsessive compulsive disorder onset, 747

at paraphilia onset, 681-682

substance abuse and, criminality and, 613-614

Aggression. See also Violence; Violent patient.

biologic correlates of, homicidal behavior and, 666

in conduct disorders. See Conduct disorders.

head injuries and, 402

neurologic disease and, 322

obsessions involving, obsessive compulsive disorder and, 750–751

AIDS. See HIV encephalopathy.

Akathisia, as medication side effect, neuroleptics and, 259

in schizophrenia, 141 tardive, 262, 493-494

violence and, 557

Alcohol abuse. See also Alcoholism; Substance abuse.

criminal behavior and, 607-611, 616-617 criminal responsibility and, 611

criminal responsibility and, 61: head injuries and, 401–402

homicide and, 665–666

pharmacologic treatment of, 181-183

Alcohol abuse (Continued) violence and, 557 Alcoholic "dementia," 368 Alcoholic pellagra encephalopathy, 366 Alcoholic polyneuropathy, 365 Alcohol intoxication, 360 Alcoholism, neurologic complications of, 359-370 alcohol intoxication, 360 alcohol withdrawal syndrome, 360, 362central pontine myelinolysis, 366-367 classification of, 359-360, 361 "dementia," 368 fetal alcohol syndrome, 367 Marchiafava-Bignami syndrome, 366-367 myopathy, 367-368 nutritional diseases, 363-366 secondary to systemic problems, 368trauma incidence and, 369-370 of uncertain pathogenesis, 366-368 Alcohol withdrawal syndrome, 360, 362-Alprazolam. See Benzodiazepines. Amantadine, in cocaine withdrawal, 183 Amblyopia, nutritional, 365-366 Amnesia. See also Memory. stroke and, 419-420 Anorexia nervosa, 154-158 antidepressant medication for, 155-156 antipsychotic medication for, 155 clinical recommendations for, 157-158 cyproheptadine for, 156-157 lithium for, 157 Antibodies, intrathecal, in HIV encephalopathy, 460 Anticholinergic side effects of neuroleptics, 263 Anticonvulsants. See also specific drugs. cognitive effects of, 390-392 for complex partial seizures, 378-380 for conduct disorders, 76-77 for obsessive compulsive disorder, 899-900 for violent patient, 561 Antidepressants, for bulimia nervosa, 150-153 in cocaine withdrawal, 184 cyclic. See also Tricyclic antidepressants; specific antidepressants. for obsessive compulsive disorder, 895-898, 909 prepubertal major depression and, 31 - 36

Antihistamines, for anxiety disorders,

Antipsychotic drugs. See Neuroleptics;

pediatric, 56-57

specific drugs.

Anxiety disorders, pediatric, antidepressants for, 50-54 antihistamines for, 56-57 barbiturates for, 56 benzodiazepines for, 43-50 buspirone for, 54-55 diagnostic issues in, 42-43 neuroleptics for, 56 pharmacotherapy of, 41-62 propranolol for, 55-56 separation anxiety, neuroleptic-induced, 258 Tourette's syndrome with, 125 trichotillomania and, 786-787 Anxiety signal, in obsessive compulsive disorder, 840-841 Anxiolytics, for obsessive compulsive disorder, 900-901 augmentation strategies using, 909 Aphasia, stroke and, 416, 417, 418 temporal lobe disease and, 319-320 Apnea, sleep, 473-475 Apraxia, limb, stroke and, 420 Arsenic exposure, 331 Arson, 623-638. See also Firesetting. associated with mental disorders, 630classification of, 627 communicative, 632-633 defined, 624 history of, 624-625 pathologic, treatment of, 636-637 for profit, 626-628 unassociated with psychological disorders, 626-630 Asphyxiophilia, 712-714 Attention, neglect and, stroke and, 416-417, 419 Attention deficit hyperactivity disorder (ADHD), in juvenile offenders, 727pharmacologic treatment of, 1-24. See also Stimulants. alternatives to stimulants in, 21-23 background of, 2-3 dosing regimen for, 15-16 drug interactions and, 20-21 indications for, 9-10 in presence of Tourette's syndrome, 122-123 short-term effects of, 10-15 stimulant pharmacology and, 3-9 therapeutic monitoring in, 16-20 Attorneys, psychiatric diagnosis and, 535 Autonomic phenomena, rebound, neuroleptic withdrawal and, 265

Balint syndrome, 318

Bankruptcy scam, arson and, 627 Barbiturates, for anxiety disorders, pediatric, 56

Basal ganglia disease, 322-326

Battered child syndrome, filicide and, 668-669

Behavior, head injuries affecting, 398-402 ictal, complex partial seizures and, 373-

multiple sclerosis and, 427-436 neuroleptic effects on, 257-258 rebound problems with, neuroleptic

withdrawal and, 265-266 stimulant effects on, 198-199 in classroom, 200

stroke and, 415-423

Behavioral assessment, in obsessive compulsive disorder, 888

Behavioral patterns, associated with intrusive thoughts, 837-839

Behavioral sleep abnormalities, 475-477 Behavior therapy, for incest offender, 694-695

mental retardation and, 517-518 for obsessive compulsive disorder, 856, 885-893

adult, 97

child and adolescent, 98, 891-892 for Tourette's syndrome and chronic motor tics, 854-856

for violent patient, 565

Benzodiazepines, for anxiety disorders, pediatric, 43-50 for conduct disorders, 78-79

for sleep disorders, 481-483 for violent patient, 560

Beta-blockers. See also specific drugs. for conduct disorders, 77-78 for violent patient, 561-562

Blindness, cortical, 318

Blood flow, cerebral, HMPAO-SPECT for,

133Xe-SPECT for, 874-875

Brain biochemistry, in obsessive compulsive disorder patients, cerebral blood flow and, 874-875 functional brain imaging and, 872-874 Brain injury. See Head injuries.

Brain lupus. See Systemic lupus

erythematosus (SLE), with central nervous system involvement. Brain physiology, in obsessive compulsive

disorder patients, cerebral blood flow and, 874-875

functional brain imaging and, 872-874 Brain structure, in vivo, in obsessive compulsive disorder patients, 871-872

Bromocriptine, in alcoholism treatment,

in cocaine withdrawal, 183

Building strippers, arson and, 628 Bulimia nervosa, 149-154, 158

antidepressant medication for, 150-153 clinical recommendations for, 153-154

Buprenorphine, in cocaine withdrawal, 184

Buproprion, stimulants versus, for ADHD, 23

Burglary, arson and, 628

Business modifications, arson and, 628 Buspirone, for alcoholism, 182-183

for anxiety disorders, pediatric, 54-55 for obsessive compulsive disorder, augmentation strategies using, 907-908

Calcium metabolism, psychiatric disorders related to, 329-330

Capsulotomy, for obsessive compulsive disorder treatment, 926 Carbamazepine. See also Anticonvulsants.

in cocaine withdrawal, 184 for complex partial seizures, 379

Cardiovascular system, cyclic antidepressant effects on, pediatric,

neuroleptic side effects and, 263-264 Catatonia, neuroleptic-induced, 262

Central nervous system, disorders of. See also Neurologic disorders. cocaine-related, 505 firesetting associated with, 633 systemic lupus erythematosus involv-

ing, 439-451 Central nervous system hypersomnia, idiopathic, 473

Central pontine myelinolysis (CPM), alcoholism and, 366-367

Cerebellar degeneration, alcoholism and, 366

Cerebral blood flow, in obsessive compulsive disorder, HMPAO-SPECT for, 875 133Xe-SPECT for, 874-875

Cerebral dysfunction, nonfocal, in lupus, 445-446

Cerebral glucose metabolic rates, FDG-PET for, in obsessive compulsive disorder patients, 876-877

Cerebrospinal fluid, in HIV encephalopathy, 459-460

Cerebrovascular disease. See also Stroke. cocaine-related, 503-504

dementia and, 421-422

11C-glucose, positron emission tomography using, in study of obsessive compulsive disorder, 878Child abuse. See Battered child syndrome; Incest.

Children. See also Juvenile entries; specific pediatric disorders.

murder of, 666-669

obsessive compulsive disorder onset in, 767–773. See also Obsessive compulsive disorder (OCD), child and adolescent.

pharmacologic treatment of. See also specific drug or type of drug. for anxiety disorders, 41-62 for depression, 29-37 for obsessive compulsive disorder, 87-103, 771-772

trichotillomania in, 779-780. See also Trichotillomania.

as victims, pedophiles' behavior against, 679-680

Chlordiazepoxide. See Benzodiazepines. Chlorpromazine. See Neuroleptics.

Chromosomal disorders, firesetting associated with, 633

Cingulotomy, for obsessive compulsive disorder, 925

Circadian rhythm sleep disorders, 480-481

Citalopram, in alcoholism treatment, 182 Clinical forensic psychiatry, 529–733. See also Forensic psychiatry.

also Forensic psychiatry, 329–733. See also Forensic psychiatry. Clomipramine, for obsessive compulsive disorder, 93, 896–897

child and adolescent, 102

Clonazepam. See Benzodiazepines.

Clonidine, for obsessive compulsive disorder, 903

augmentation strategies using, 908 stimulants versus, for ADHD, 23 for tic disorders, 120–121

Clorazepate. See Benzodiazepines.

Clozapine, for schizophrenia, pediatric, 141

Cocaine abuse. See also Substance abuse. neurologic complications associated with, 503–505

pharmacologic treatment of, 183-184 violence and, 557

Cognitive-behavioral patterns, in obsessive compulsive disorder, 837– 843

Cognitive distortions, sexual violence and, 705-706

treatment of, 709

Cognitive function, frontal lobe disease and, 316–317

hallucinations and, 349

head injuries and, 397–398 medication side effects and, antiepileptic drugs, 390–392 neuroleptics, 257–258 in schizophrenia, 142 multiple sclerosis and, 428–431 cognitive retraining in, 435

after psychosurgery, in obsessive compulsive disorder, 931–932

stimulant effects on, 198

Cognitive therapy, of incest offenders, 694 Colloid cysts, 326–327

Communicative arson, 632-633

Complex partial seizures, 373–381 antiepileptic drug therapy for, 378–380 differential diagnosis of, 375–378 EEG in, 376–378 examination in, 374, 375

examination in, 374, 375 history in, 374–375

ictal behavior in, 373–374 neuroimaging in, 378 social consequences of, 380

surgery for, 380 treatment of, 378–380

Comprehensive Psychopathological Rating Scale, OCD subscale of, 863

Compulsive desires, crime for gratification of, 543–545

Compulsive gambling. See Gambling, pathological.

Compulsive personality disorder, obsessive compulsive disorder and, 753–754

Computed tomography, of brain structure, in obsessive compulsive disorder patients, 871–872 in HIV encephalopathy, 458–459

of violent patient, 555 Conditional release, 593

Conduct disorders, assessment of, 70 in juvenile offenders, 724–727

pharmacologic treatment of, 69–80 anticonvulsants in, 76–77 benzodiazepines in, 78–79

beta-blockers in, 77–78 considerations before initiation of, 70–71

lithium carbonate in, 74–76 neuroleptics in, 73–74 stimulants in, 71–73

types of treatments for, 70 Confusional arousals, during sleep, 477 Consent. See also *Informed consent*.

neuroleptic administration and, pediatric, 269

Contamination, obsessions with, in obsessive compulsive disorder, 749

Conversion reactions, comorbidity with, 304–306

compensation and, 306 demographics of, 302–303 false-positive, 303–304 family history of, 306 follow-up of, 306–307 occurrence of, 302–303
psychosocial factors in, 306
Correctional settings. See *Prisons*.
Cortical behavioral syndromes,
nonhemiplegic, stroke and, 421
Cortical blindness, 318
CPM (central pontine myelinolysis),
alcoholism and, 366–367
CPRS-OCD subscale, 863

CPRS-OCD subscale, 863 Crack cocaine. See also Substance abuse. violence and, 557

Crime. See also Forensic assessment; Forensic psychiatry; Offender; specific crime.

concealment of, firesetting in, 628 to gratify compulsive desires, 543–545 major affective disorders and, 569–572 mental disorder and, coincidental, 547–548

reflecting personality disorder, 545–547 in response to psychotic symptoms, 540–543

schizophrenia and, 576–580 true or feigned mental disorder in response to, 548–550

Criminal behavior. See also Violence. gambling and, 652–654. See also Gambling.

sexually deviant, 675–687. See also Paraphilias.

substance abuse and, 605–619 alcohol, 607–611, 616–617 causality and, 612 demographics and, 613–616 forensic psychiatric evaluation in, 617–619 steroids, 616

Criminal responsibility, alcohol and, 611 major affective disorders and, 572–573 Cutaneous disorders, neuroleptic-

induced, 264

Cyclic antidepressants. See Tricyclic antidepressants.

Cyproheptadine, for anorexia nervosa, 156–157 Cysts, colloid, 326–327

Delirium, 335-344

clinical features of, 337–339 course and outcome of, 339–340 defined, 336–337 diagnosis of, 342–343 differential diagnosis of, 343 etiology of, 340–341 importance of, 335–336 incidence of, 337 pathogenesis of, 341–342 prevalence of, 337

terminological confusion surrounding, 336

treatment of, 343-344

Delusions, arson associated with, 630

Dementia, alcoholic, 368 cerebrovascular disease and, 421–422 HIV encephalopathy and, 455–463. See

also HIV encephalopathy. multiple sclerosis and, 430

sleep in, 479–480 Demographics, obsessive compulsive disorder and, 745–747

substance abuse and, criminality and, 613-616

Depression. See also *Mood disorders*. arson associated with, 630

child and adolescent, cyclic antidepressants in, 31–36

monoamine oxidase inhibitors in, 36–37

pharmacologic treatment of, **29–37** relationship to adult depression, 30–31

diagnostic criteria of, 30

FDG-PET study of, in obsessive compulsive disorder, 878

head injuries and, 404–405 treatment of, 407 multiple sclerosis and, 432

stroke and, 422 Tourette's syndrome with, 125

Desipramine, in cocaine withdrawal, 184 stimulants versus, for ADHD, 22–23

Developmental disorders, arson associated with, 631 stimulants in, 208–210

Developmental factors, in homicidal behavior, 662-664

Developmental psychopathology of obsessive compulsive disorder, 754– 755

Dextroamphetamine. See *Stimulants*. Diazepam. See *Benzodiazepines*.

Dimensional personality assessment, in obsessive compulsive disorder, 805– 806

Disinhibition, head injuries and, 321–322 treatment of, 407–408 multiple sclerosis and, 433 neurologic disease and, 321–322

Dissociation, sleep disorders and, 477–478 Doubt, pathologic, obsessive compulsive disorder and, 749–750

Drug abuse. See Substance abuse.

Drugs. See also specific drug or type of drug.

neurologic complications of, **491–506** cocaine-related syndromes, 503–505 neuroleptic malignant syndrome, 498–503 Drugs (Continued)

tardive dyskinesia, 492-498

in psychiatric treatment of mentally retarded, 518-519

in systemic lupus erythematosus management, causing neuropsychiatric disease, 445

for treatment of obsessive compulsive disorders, 895-914

for violent patient, 558-562

visual hallucinations induced by, 353

Drunken driving, 611. See also Alcohol abuse.

DSM-III personality disorders, assessment of, in obsessive compulsive disorder, 806-808

DSM-III-R, hypochondriasis criteria of, 791-792

role of, in legal proceedings, 530-532 Dyskinesia, tardive. See Tardive dyskinesia.

withdrawal, neuroleptics and, 265 Dysphoria, neuroleptic-induced, 258

Dystonias, cocaine-related, 505 neuroleptic-induced, 259 paroxysmal, nocturnal, 477

tardive, 262, 493

Eating disorders, anorexia nervosa, 154-

bulimia nervosa, 149-154, 158

pharmacologic treatment of, 149-158 Educational services, in schizophrenia,

pediatric, 144

Educational status, substance abuse and, criminality and, 614

Elderly. See Senescence.

Electroencephalogram (EEG), in complex partial seizures, 376-378

in violent patient, 555 Emergency medication, of violent patient,

558-560 Emergency room, admission to, violence

on, 581-582 Emotional expression, disinhibition of.

See Disinhibition.

Employment, arson and, 628

Encephalitis, 327

herpes simplex, 327

limbic, paraneoplastic, 322 rabies, 327

Encephalopathy, HIV. See also HIV encephalopathy.

dementia and, 455-463 pellagra, alcoholic, 366 Wernicke's, 364-365

Endocrine disorders, firesetting associated with, 633-634

Endocrine function, neuroleptic effects on, 264-265

Enuresis, 174-176

Environment, homicidal behavior and, 664

Epilepsy. See also Anticonvulsants; Seizures.

age at onset of, neuropsychological functioning and, 388-389

duration of disorder, neuropsychological functioning and, 389-390

neuropsychological aspects of, 383-392 neuropsychological assessment in, 383-386

social consequences of, 380

Epilepsy surgery, complex partial seizures and, 380

Ethnicity, substance abuse and, criminality and, 614-615

Euphoria, multiple sclerosis and, 431–432 Executive functions, neuropsychological

assessment of, 293-294 Extrapyramidal side effects of

neuroleptics, 141, 258-263 Eyes, neuroleptic side effects and, 264

Family, in assessment of child and adolescent obsessive compulsive disorder, 100-101

incest, characteristics of, 692-694 Family dynamics, of incest family, 693-

Family-focused treatment of incest, 695-697

Family history, trichotillomania and, 782-

Family studies, of obsessive compulsive disorder and Tourette's syndrome, 763, 850-851

FDG. See 18Fluorodeoxyglucose. Fenfluramine, for obsessive compulsive disorder, 902-903

augmentation strategies using, 909 Fetal alcohol syndrome, 367

Filicide, 667-669. See also Homicide.

Fire buffs, 629

Fireplay, juvenile, 635

Firesetting, arson versus, 624. See also Arson.

associated with medical and neurologic disorders, 633-634

classification of, 625-635

juvenile, 634-635

personality disorders and, 635-636 by women, 635

Fitness to stand trial, major affective disorders and, 572

<sup>18</sup>Fluorodeoxyglucose (FDG), positron emission tomography using, in OCD, for cerebral glucose metabolic rates, 876–877

for studies of treatment effects, 879-882 for study of depression, 878

Fluoxetine, in alcoholism, 182 in obsessive compulsive disorder, 93– 94, 897

child and adolescent, 101–102

in prepubertal major depression, efficacy of, 33-34

Flurazepam. See Benzodiazepines.

Fluvoxamine, in alcoholism treatment, 182 for obsessive compulsive disorder, 95, 898

Forensic assessment, 532–533 of juvenile offenders, **721–733**. See also Juvenile offenders.

violent patient and, 553-557 substance abuse and, 617-619

Forensic psychiatry. See also Legal proceedings; Offender.

assessment in. See Forensic assessment. clinical, 529–733

diagnosis in, use and reliability of, 529-536

major affective disorders and, 569–573 schizophrenia in, 575–587 schizophrenic insanity acquittees in,

591–603 Frontal lobe, diseases of, 311, 314–317 dysfunction of, in obsessive compulsive

disorder, 830-831, 832-834 tumors of, 326

Functional brain imaging, in obsessive compulsive disorder, 872–874

Gambling, pathological, 647–658
criminal activity and, 652–654
defined, 648–650
desperation phase in, 651
giving up phase in, 652
losing phase in, 651
nature and course of, 650–652
prison and, 654–655
treatment of, 655–657
winning phase in, 651
Gender, obsessive compulsive disorder and, 745
stimulants and, 196, 198
substance abuse and, criminality and,

Genetics, of obsessive compulsive disorder, and Tourette's syndrome, 759–764, 850–851 Gilles de la Tourette syndrome. See Tourette's syndrome.

Glucose, cerebral, FDG-PET for metabolic rates in obsessive compulsive disorder patients, 876–877

Growth, neuroleptic effects on, 264–265 stimulant effects on, 211–212

Gustatory hallucinations, 354. See also Hallucinations.

Hallucinations, 347-355 arson associated with, 630 clinical considerations of, 349-354 cognitive theories of, 349 diagnostic significance of, 349-351 etiology of, 348-349 gustatory, 354 neurophysiologic hypotheses of, 348-349 occipital lobe disease and, 318-319 olfactory, 354 in organic disorders, 351-352 psychodynamic significance of, 349 somatosensory, 353-354 treatment of, 354-355 visual, 352-353 Haloperidol. See also Neuroleptics.

for tic disorders, 119–120
Handedness, assessment of, 286
Headache, cocaine-related, 505
Headbanging, pediatric, 176

Head injuries, behavioral sequelae of, 398–402

cognitive sequelae of, 397–398 major psychiatric disorders and, 404– 406

neuropsychiatric sequelae of, 395–409 age effects on, 406–407 treatment issues in, 407–408 pathophysiology of, 395–397 postconcussive syndrome and, 402–404 severity of, behavioral sequelae and,

Hematologic disorders, neurolepticinduced, 265

398-400

Hepatic disorders, neuroleptic-induced, 265

Hero syndrome, firesetting and, 629 Herpes simplex encephalitis, 327 HIV encephalopathy, acute HIV meningoencephalitis versus, 456 cerebrospinal fluid in, 459–460 clinical neurophysiology studies in, 459 dementia and, 455–463

clinical and neuropsychological features of, 456–458 differential diagnosis of, 456

functional neuroimaging in, 459

HIV encephalopathy (Continued) imaging studies in, 458-459 management and treatment of, 462-463 neuropathology of, 460-461 pathogenesis of, 461 psychiatric presentation of, 456 psychometric testing in, 456-458 HIV meningoencephalitis, acute, 456 HMPAO-SPECT, for cerebral blood flow, in obsessive compulsive disorder, 875 Hoarding, obsessive compulsive disorder and, 752 Homicide, 661-671. See also Violence;

alcohol and, 665-666 filicide, 667-669 homicidal behavior and, 662-666 clinical factors in, 664-666 developmental factors in, 662-664 environmental factors in, 664 infanticide, 666-669 mental illness and, 664-665 prevention of, 669-670 schizophrenia and, 580-581

Violent patient.

sexual, 710-711 Hormonal levels, of sexually violent men, 704-705

treatment and, 707-708 Human immunodeficiency virus, encephalopathy in. See HIV encephalopathy.

Huntington's chorea, 323-324 Hyperactivity. See Attention deficit hyperactivity disorder (ADHD). Hypersomnia, 472-475. See also Sleep

disorders. Hypersomnolence, idiopathic, in children and adolescents, 170

Hypnotics, for sleep disorders, 481-483 Hypochondriasis, defined, 791 nosologic status of, 791-792 obsessive compulsive disorder and,

791-799

empirical evidence of overlap and comorbidity of, 794-797

phenomenology of, comparison to obsessive compulsive disorder phenomenology, 793-794

primary versus secondary, 791 subtypes of, 797-798 treatment of, 798-799

Hypotension, neuroleptic-induced, 263 Hypothalamic-pituitary-gonadal function, neuroleptic effects on, 264-265

Hypothalamus, diseases of, 321-322

Ictal behavior, complex partial seizures and, 373-374

Imaging. See Neuroimaging; specific disorder; specific method. Impulsive control disorder, trichotillomania and, 786-787

Impulsivity, arson associated with, 632 head injuries and, 400-401 treatment of, 407-408

Incest, defined, 689

future research directions for, 697-698 treatment of, family-oriented, 695-697 offender-oriented, 694-695

Incest perpetrators, 689-699 characteristics of, 690-692

family of, characteristics of, 692-694 Infanticide, 666-669. See also Homicide. Infections, firesetting associated with, 633

psychiatric manifestations of, 327-328 Information processing, normal and

abnormal, obsessive compulsive disorder and, 825-844

speed of, neuropsychological assessment of, 294

Informed consent. See also Consent. psychopharmacology and, schizophrenia and, 137-138

Inhalants. See also Substance abuse. violence and, 557

Inpatients, schizophrenic, violence among, 582-584

Insanity acquittees, schizophrenic, involved in mental health and criminal justice systems, 591-603

Insomnia, 470-471. See also Sleep disorders.

pediatric, 164-166

Insurance fraud, arson and, 626 Intelligence. See also Mental retardation. general, multiple sclerosis and, 428-429 neuropsychological assessment of, 288-290

obsessive compulsive disorder and, 746 Intermittent explosive disorder, arson associated with, 632 Intoxication, alcohol, 360

Intrusive thoughts, behavioral patterns associated with, 837-839

Jails. See Prisons.

Judges, psychiatric diagnosis and, 535 Judgment, disorders of, arson associated

with, 631

Juries, psychiatric diagnosis and, 535-536 Juvenile fireplay, 635

Juvenile firesetting, 634-635

Juvenile offenders, forensic assessment of, 721-733 ADHD in, 727-728

clinical issues in, 724-727

mood disorders in, 728–729 neuropsychiatric disorders in, 729–730 sexual offenses and, 730–732

Kleine-Levin syndrome, in children and adolescents, 170 Klüver-Bucy syndrome, 321 Korsakoff syndrome, 364, 365

Laboratory testing, of violent patient, 555
Lateralized dysfunction, obsessive
compulsive disorder and, 834–835
Lawyers, psychiatric diagnosis and, 535
Learning, neuroleptic effects on, 258
Legal proceedings. See also Forensic
assessment; Forensic psychiatry.
DSM-III-R role in, 530–532
testimony in, 533–535
violence prediction and, 565–566
Leyton Obsessional Inventory, 861–862
Limb apraxia, stroke and, 420
Limbic encephalitis, paraneoplastic, 322
Limbic leucotomy, in obsessive
compulsive disorder treatment, 925–
926

Limbic system, diseases of, 321–322 Linguistic function, neuropsychological assessment of, 292–293 Lithium, 223–237 in alcoholism treatment, 181 for anorexia nervosa, 157 for conduct disorders, 74–76

for conduct disorders, 74–76 cyclic antidepressant augmentation with, in prepubertal major depression, 36

for obsessive compulsive disorder, 899 augmentation strategies using, 906– 907

pharmacokinetics of, 223–226 in children and adolescents, 233–237 side effects of, pediatric, 234–237 stimulants versus, for ADHD, 23 for violent patient, 562 Liver function, neuroleptic effects on, 265 Lorazepam. See Benzodiazepines.

Lupus erythematosus. See Systemic lupus erythematosus (SLE).

Magnetic resonance imaging, of brain structure, in obsessive compulsive disorder patients, 872 in complex partial seizures, 378 in HIV encephalopathy, 458, 459 of violent patient, 555 Malignant obsessive compulsive disorder, neurosurgical treatment of, 921–935 Mania, arson associated with, 630–631 head injuries and, 405 treatment of, 407

Marchiafava-Bignami syndrome, alcoholism and, 366–367 Marital relationship, in incest family, 692–

693

Marital status, obsessive compulsive disorder and, 746 substance abuse and, criminality and, 614

Maudsley Obsessional-Compulsive Inventory, 862–863

Medical disorders, firesetting associated with, 633–634

Meige's syndrome, 326

Memory, deficits in, cognitive-behavioral accounts of obsessive compulsive disorder and, 839-840 multiple sclerosis and, 429-430 neuropsychological assessment of, 290-

292 in obsessive compulsive disorder,

831-834 stroke and, 419-420

temporal lobe disease and, 320-321 Meningitis, chronic, 328

Meningoencephalitis, HIV, acute, 456 Mental disorders. See also specific disorder.

arson associated with, 630–633 crime and, coincidental, 547–548 in offenders, types of, 539–550 violence and, 553–566 true or feigned, in response to crime,

548-550 Mental Health Information System (MHIS), 595

Mental health system, criminal justice system and, involvement of schizophrenic insanity acquittees in, 591–603

Mental illness, homicide and, 664–665 Mental retardation, **511–519** causes of, 513–515 classification of, 512–513 defined, 511–512 psychiatric assessment in, 516 psychiatric treatment in, 516–519

psychiatric treatment in, 516–519 psychopathology in, 515–516 Mercury exposure, 331

Metabolic disease, firesetting associated with, 633–634 psychiatric manifestations of, 328–330

Methylphenidate. See also *Stimulants*. clinical practice with, 9

MHIS (Mental Health Information System), 595 Minnesota Multiphasic Personality Inventory (MMPI), in obsessive compulsive disorder, 804-805 Molindone. See Neuroleptics. Monoamine oxidase inhibitors, in child and adolescent depression, 36-37

in obsessive compulsive disorder, 898-

Mood disorders. See also Depression; Mania.

arson associated with, 630-631 incest associated with, 690-691 in juvenile offenders, 728-729 pediatric, schizophrenia versus, 133, 134-135

treatment of, head injuries and, 407 Morbidity and mortality, in substance abuse, 612-613

Mother-child interactions, stimulants and, 199

Motor function, alteration in, frontal lobe disease and, 314, 315 sleep abnormalities relating to, 475-477

tics and. See Tic disorders.

Multiple sclerosis, behavioral manifestations associated with, 427-436

assessment of, 433-434 historical background of, 427-428 management of, 434-435 methodologic issues in, 428 cognitive dysfunction in, 428-431 neuropsychiatric disorders in, 431-433 Multiple tic syndromes. See Tic disorders.

Murder. See Homicide. Myoclonus, tardive, 494 Myopathy, alcoholic, 367-368

Naloxone, for obsessive compulsive disorder, 902

Naltrexone, in alcoholism treatment, 183 Narcolepsy, 472-473

in children and adolescents, 168-170 National Institute of Mental Health Global Obsessive Compulsive Scale, 863–864 Necrophilia, 711-712

Neglect syndrome, stroke and, 416-417, 419

Neural circuits, specific, obsessive compulsive disorder and, 827-829 Neurodegenerative disorders, 328, 329

Neuroimaging, in complex partial seizures, 378

in HIV encephalopathy, 458-459 in obsessive compulsive disorder, 818, 820, 827, 871-882

Neuroleptic malignant syndrome, 262-263, 498-503

clinical features of, 498-500 differential diagnosis of, 500-502 epidemiology of, 498 pathophysiology of, 502 treatment of, 502-503

Neuroleptics. See also Drugs; specific drug

in AIDS, 462

anticholinergic side effects of, 263 behavioral/cognitive side effects of, 257-

cardiovascular/respiratory side effects of, 263-264

classes and chemical structures of, 243-244

clinical indications for, 247-257 cutaneous side effects of, 264 endocrine side effects of, 264-265 hematologic side effects of, 265 hepatic side effects of, 265 mechanisms and effects of, 137, 245-

247 neurologic side effects of, 258-263

nonresponders to, schizophrenia and,

for obsessive compulsive disorder, 900 augmentation strategies using, 909-

ocular side effects of, 264 overdose of, 266

in pediatric psychiatry, 243-270 administration of, 266-270

for anorexia nervosa, 155 for anxiety disorders, 56

for conduct disorders, 73-74

discontinuation of, 270 duration of treatment with, 269-270

indications for, 247-257 overdose of, 266

for schizophrenia, 137-140 side effect management in, 257-266

pharmacodynamics of, 245 pharmacokinetics of, 245

pharmacology of, 243-247 relative potencies of, 244-245

side effects of, 141-142, 257-266 violence related to, 557

for violent patient, in emergency management, 559

in long-term management, 560-561 withdrawal from, symptoms of, 265-

Neurologic disorders. See also specific

drug-induced, 491-506

firesetting associated with, 633-634 presenting as psychiatric disorders, 311-331

hallucinations, 348-349, 351-352

simulation of, 301-309. See also Conversion reactions.

Neurology, psychiatry and, interface of, 283-519

Neuropsychiatric disorders, in juvenile offenders, 729–730

Neuropsychological assessment, 283–296 basic concepts of, 284–286 capacities probed by, 288–295

defined, 284

in epilepsy, 383-386

estimation of premorbid ability level and, 285–286

executive functions in, 293-294

handedness in, 286

in HIV encephalopathy, 456-458

indications for, 286-288

information processing speed in, 294 intellectual abilities in, 288-290

memory in, 290-292

OCD and, 831-834 in multiple sclerosis, 434

in obsessive compulsive disorder, 804–805, 830–837

implications of findings from, 835– 837

rating scales for, 861-868

orientation in, 290

personality in, 294-295

speech and linguistic functions in, 292– 293

standardization and, 284-285

strategies of, 288

visuoperceptive, visuospatial, and visuoconstructive functions in, 293 OCD and, 831–832

Neurosurgery. See Psychosurgery.

Neurosyphilis, 327-328

Niacin deficiency, 330

alcoholism and, 366

Nightmares, 476 in children, 174

NIMH-Global Obsessive Compulsive

Scale, 863–864 Nocturnal paroxysmal dystonia, 477

Nutritional amblyopia, 365–366

Nutritional diseases, alcoholism and, 363-366

Observer-rated scales, obsessive compulsive disorder and, 863–867 Obsessional disorders, 743–935. See also Obsessive compulsive disorder (OCD). behavior therapy for, 892

trichotillomania, 777–788 Obsessive compulsive disorder (OCD), 743–756

age of onset of, 747

behavior therapy for, 97-98, 856, 885-893

assessment before, 888 efficacy of, 887-888

in patients without behavioral rituals,

principles of, 885-887

biochemical findings in, 90-91

challenge studies of, 91

child and adolescent, 767-773 assessment of, 98-101, 867

associated impairment with, 88-89 behavior therapy for, 98, 891-892

clinical presentation of, 88, 767-769 comorbidity with, 89-90, 769-770

comparison of medications for, 95-97 epidemiology of, 87

phenomenology of, 88–90

prognosis of, 772-773

psychopharmacologic treatment of, 87–103, 771–772

studies of treatment for, 92–95 treatment of, **87–103**, 770–772, 891–

clinical features of, 747-756

clomipramine for, 93, 102, 896-897 cognitive-behavioral patterns in, 837-

843 comorbidity with, 753–754. See also specific comorbid conditions.

heterogeneity and, 755–756 hypochondriasis and, 794–797

personality disorders and treatment outcome and, 808–810

course of, 747 demographics of, 745-747

developmental psychopathology of, 754–755

diagnosis of, treatment outcome and, 904

dimensional personality assessment in, 805-806

DSM-III personality disorders in, assessment of, 806-808

epidemiology of, 744-747, 850

fluoxetine for, 93–94, 101–102, 897 fluvoxamine for, 94, 898 frequency of, in psychiatric popula-

tions, 744 frontal dysfunction in, 830-831, 832-834

functional imaging in, 818, 820 functional neuroanatomic studies of, 816, 818–821, 882

genetics of, Tourette's syndrome and, 759–764, 850–851

hypochondriasis and, **791–799** empirical evidence of overlap and comorbidity of, **794–797** 

information processing in, 825-844 lateralized dysfunction in, 834-835 Obsessive compulsive disorder (OCD) (Continued) malignant, neurosurgical treatment of, 921-935 memory deficits in, 831-834 MMPI findings in, 804-805 natural history of, 747 neuroanatomic and neurologic findings in, 91-92, 816, 818-821, 826-829, 882 neurobiology of, 90-92, 813-821 neuroimaging studies of, 818, 820, 827, 871-882 cerebral blood flow in, 874-875 cerebral glucose metabolic rates in, 876-878 11C-glucose-PET study in, 878-879 critique of, 880-882 depression and, 878 functional brain imaging in, 872-874 in vivo brain structure in, 871-872 treatment effects in, 879-882 neuropathology of, 853 Tourette's syndrome and, 853-854 neuropharmacologic studies of, 813-816, 817 neuropsychological assessment in, 804-805, 830-837 implications of findings from, 835-837 neuropsychological perspective on, 825personality disorders in, 803-811 pharmacotherapy for, 87-103, 895-914 augmentation strategies in, 904-911, 912-913 duration of, 911, 914 in presence of Tourette's syndrome, 123-125 response to, 854 in treatment-resistant patients, 903phenomenologic subtypes of, 748-752 hypochondriasis phenomenology and, 793-794 Tourette's syndrome and, 851-852 prevalence of, in general population, 744-745 psychosurgical treatment of, 818, 921contraindications to, 924 current procedures for, 924-926 future of, 935 indications for, 923-924 methodologic problems in, 927-931 patient selection for, 922-923 poor response to, 934

preoperative work-up for, 933-934

reasons for effect of, 934

treatment following, 928-929

risks of, 931-933

serotonin functioning in, 815-816, 817 sertraline for, 898 severity and change in, assessment of, 861-868 symptoms of, functional neuroanatomy mediating, 882 tics and, 850 Tourette's syndrome and, clinical aspects of, 849-857 familial/genetic relationship between, 763, 850-851 genetics of, 759-764 neuropathology of, 853-854 treatment response of, 854-857 treatment outcome in, comorbid personality disorders and, 808-810 diagnosis and, 904 PDG-PET studies of, 879-882 surgery and, 927 Tourette's syndrome and, 854-857 trichotillomania and. See Trichotillomania. visuospatial deficits in, 831-832 Obstructive sleep apnea syndrome, 473-Occipital lobe disease, 318-319 Ocular disorders, neuroleptic-induced, 264, 494 Oculogyric crisis, tardive, 494 Offender. See also Crime; Criminal behavior; specific offense. fitness to stand trial, major affective disorders and, 572 juvenile. See also Juvenile offenders. forensic assessment of, 721-733 mentally disordered, patterns among, 539-550 violence and, 553-566 pathological gambler as, 647-658. See also Gambling, pathological. responsibility of. See Criminal responsi-Olfactory hallucinations, 354. See also Hallucinations. Ordinal position, obsessive compulsive disorder and, 747 Oregon Psychiatric Security Review Board (PSRB), 591 composition of, 592 conditional release and, 593 Mental Health and Developmental Disabilities Division and, 592 schizophrenic insanity acquittees and, 593-603 after discharge, 598-600 Organic disorders. See also Neurologic disorders; specific type. hallucinations in, 351-352

pediatric, schizophrenia versus, 135

Organic therapy, of incest offenders, 694

Orientation, neuropsychological assessment of, 290 Outbursts. See *Conduct disorders*. Oxytocin, for obsessive compulsive disorder, 901–902

Palsy, supranuclear, progressive, 325 Panencephalitis, subacute sclerosing, 328 Paraneoplastic limbic encephalitis, 322 Paraphilias, 675–687 age of onset of, 681–682

categories of, median number of paraphilic acts by, 680–681

criminal justice system and, 678 cross diagnosis of, 682–687 defined, 675–677

diagnostic criteria for, 676 in general population, 677–678 necrophilia, 711–712

patients with, behavior in psychiatric settings, 679

Parasomnias, in children and adolescents, 171–177

Parietal lobe disease, 317–318 Parkinson's disease, 325

Parkinson syndrome, neurolepticinduced, 259, 494

Paroxysmal dystonia, nocturnal, 477 Partial seizures, complex, 373–381. See also Complex partial seizures.

Pathological gambler. See also Gambling, pathological. as criminal offender, 647–658

Pediatrics. See also *Children*; specific pediatric disorders.

psychopharmacology in, 1–270 Pedophiles. See also Paraphilias.

behavior of, against child victims, 679–680

Peer relationships, stimulants and, 199-200

Pellagra encephalopathy, alcoholic, 366 Pemoline. See Stimulants.

Perceptual disorders, arson associated with, 630

Peripheral nervous system disorders, cocaine-related, 505

Personality, changes in, frontal lobe disease and, 315–316 head injuries and, 400

multiple sclerosis and, 432–433 dimensional assessment of, in obsessive compulsive disorder, 805–806

neuropsychological assessment of, 294– 295

in OCD, 804–805 surgical risks involving, in obsessive compulsive disorder, 932–933 Personality disorders, compulsive, obsessive compulsive disorder and, 753–754

crime reflecting, 545-547

DSM-III, assessment in obsessive compulsive disorder, 806–808 firesetting and, 635–636

in obsessive compulsive disorder, 753–754, 803–811

treatment outcome and, 808–810 Phencyclidine. See also Substance abuse. violence and, 557

Phenothiazines, for tic disorders, 121 Phenytoin, for complex partial seizures, 379

Phobia, social, neuroleptic-induced, 258 Physical examination of violent patient, 555

Pimozide. See also *Neuroleptics*. for tic disorders, 120 Pituitary disease, 329

Political purposes, firesetting for, 629–630 Polyneuropathy, alcoholic, 365

Porphyrias, 330

Positron emission tomography, <sup>11</sup>Cglucose, in study of obsessive compulsive disorder, 878–879

FDG, for cerebral glucose metabolic rates in OCD, 876–877 in studies of OCD treatment effects,

879-882 in study of depression in OCD, 878

in HIV encephalopathy, 459 Postconcussive syndrome, 402–404 Precision, need for, obsessive compulsive disorder and, 751

Prepubertal depression, major, cyclic antidepressants and, 31–36

Prisons, pathological gambler in, 654–655 schizophrenia in, 584–586

Progressive supranuclear palsy, 325 Property improvements, arson and, 628 Propranolol. See also *Beta-blockers*.

for anxiety disorders, pediatric, 55–56 Protest, firesetting in, 630

Psychiatric disorders. See also specific disorder.

in violent patient, 556

Psychiatric Security Review Board (PSRB). See Oregon Psychiatric Security Review Board.

Psychiatry, neurology and, interface of, 283–519

Psychoactive substances, arson associated with, 631

Psychometric testing. See also Neuropsychological assessment. in HIV encephalopathy, 456–458 Psychopathology, developmental, of obsessive compulsive disorder, 754– 755

of incest offenders, 690-691

Psychopharmacology. See also *Drugs*. pediatric, 1–270

Psychosis, multiple sclerosis and, 432 supersensitivity. See Supersensitivity psychosis.

symptoms of, crime in response to, 540-543

Psychosocial features of incest offenders, 692

Psychosocial therapies, for schizophrenia, pediatric, 143–144

Psychostimulants. See Stimulants.

Psychosurgery, defined, 922

in obsessive compulsive disorder treatment, 818, 921–935

Psychotherapy, mental retardation and, 517

Psychotic syndromes, head injuries and, 405

Pyromania, arson associated with, 632

Rabbit syndrome, neuroleptic-induced, 262

Rabies encephalitis, 327

Race, obsessive compulsive disorder and, 746

substance abuse and, criminality and, 614-615

Rage, in neurologic disease, 322

Rage outbursts. See also Conduct disorders. pharmacologic treatment of, 69–80

Rape. See Sexual violence.

Rebound, stimulants and, 212

Recognition, firesetting for, 629

Rehabilitation services, in schizophrenia, pediatric, 144

Relapse prevention training, for sex offenders, 709–710

Religion, in obsessive compulsive disorder epidemiology, 746

Religious obsessions, obsessive compulsive disorder and, 752

REM sleep behavior disorder, 475–476 Respiratory system, neuroleptic side

effects and, 263–264
Responsibility, criminal. See Criminal

responsibility.
pathologic, obsessive compulsive disor-

der and, 749-750 Restraint, of violent patient, 562-565

Revenge, firesetting for, 628–629 Riots, firesetting in, 629–630 Safety, violent patient and, 558 Saliva, lithium level in, monitoring of, 234

Schizoaffective disorder, pediatric, 145 schizophrenia versus, 135

Schizophrenia, in correctional settings, 584–586

crime and, 576-578

forensic psychiatric aspects of, 575–587 homicide and, 580–581

obsessive compulsive disorder versus, 805

pediatric, 131-145

clinical features of, 135-136

clozapine for, 141

diagnosis of, 132-136

differential diagnosis of, 134-135

historical review of, 131-132

medication choice in, 139-140 psychopharmacology of, 137-143

psychosocial therapies for, 143-144 treatment of, 136-144

psychopathology of, crime and violence in relation to, 578–580

Schizophrenic insanity acquittees, involvement in mental health and criminal justice systems, 591–603

Schizotypal personality disorder, obsessive compulsive disorder with, schizophrenia versus, 805

School avoidance, neuroleptic-induced, 258

Seclusion, of violent patient, 562-565

Sedation, neuroleptic-induced, in children, 257–258

Sedatives, for pediatric sleep disorders, 165

Seizures. See also Epilepsy. cocaine-related, 504–505

etiology of, neuropsychological functioning and, 387–388

frequency of, neuropsychological functioning and, 390

history of, neuropsychological correlates of variables in, 386–390

neuroleptic-induced, 262

nocturnal, pediatric, 176

partial, complex, 373-381. See also Complex partial seizures.

sleep-related, 477 stimulants in, 210

type of, neuropsychological functioning and, 386–387

Self-rated scales, obsessive compulsive disorder and, 861–863

Senescence. See also Age. sleep in, 478–479

Separation anxiety, neuroleptic-induced, 258 Serotonin functioning, in obsessive compulsive disorder patients, 815– 816, 817

Serotonin uptake inhibitors, mechanism of action of, 814–815 Sertraline, for obsessive compulsive

disorder, 898

Sex differences. See Gender.

Sexual arousal patterns, of sexually violent men, 704

modification of, 706–707

Sexual behavior, deviant and criminal, 675-687. See also Incest; Incest perpetrators; Paraphilias; Sexual violence. head injuries and, 322

neurologic disease and, 322

Sexual homicide, 710-711

Sexual obsessions, obsessive compulsive disorder and, 750–751

Sexual offenders. See also Sexual violence; specific offense. juvenile, 730–732

Sexual preference, of incest offenders, 690

Sexual violence, 703–714 asphyxiophilia and, 712–714 evaluation of, 704–706

necrophilia and, 711–712

treatment of, 706–710 SIDP. See Structured Interview for DSM-III Personality Disorders.

Simultanagnosia, stroke and, 420 Single-photon emission computed

tomography, in HIV encephalopathy, 459

in OCD patients, HMPAO-SPECT for cerebral blood flow and, 875 <sup>133</sup>Xe-SPECT for cerebral blood flow and, 874–875

Skin, neuroleptic effects on, 264

SLE. See Systemic lupus erythematosus. Sleep, anatomy and physiology of, 468– 469

in dementia, 479-480

physiology and development of, in children and adolescents, 162–164 in senescence, 478–479

Sleep apnea, 473–475

Sleep deprivation, chronic, 472–473

Sleep disorders, 467–483 circadian rhythm, 480–481 dissociated states, 477–478 hypersonnia, 472–475

hypersomnia, 472–475 hypnotics for, 481–483

insomnia, 470–471

international classification of, 469-470, 487-489

motor and behavioral abnormalities, 475–477

pediatric, general assessment of, 164 insomnia, 164–166

parasomnias, 171–177 pharmacologic treatment of, **161–17**7 sleepiness, 166–171

Sleep terrors, 476–477 Sleepwalking, 476–477

Social phobia, neuroleptic-induced, 258 Social skills, in offender-oriented incest treatment, 695

sexual violence and, 705-706 treatment of, 708-709

Social status, substance abuse and, criminality and, 615–616

Somatic obsessions, obsessive compulsive disorder and, 751–752

Somatosensory hallucinations, 353–354. See also *Hallucinations*.

Speech, neuropsychological assessment of, 292–293

Status dissociatus, 478

Steroid abuse, criminality and, 616 Stimulants, 191–217. See also Attention deficit hyperactivity disorder (ADHD), pharmacologic treatment of.

absorption and metabolism of, 5–7 adverse effects of, 12–15, 210–212

growth and, 211–212 management of, 214–215 alternate medications versus, 21–23 behavioral effects of, 198–199

classroom behavior and, 200 clinical guidelines for, 212–216 cognitive effects of, 198

comorbidity effects of, 200–201, 202 for conduct disorders, 71–73

developmental disorders and, 208–210 developmental effects of, 201, 203–207 drug interactions with, 194–195

efficacy of, 195-201 in adolescence, 204-205, 206

in adults, 205, 207 in latency age, 204

in preschoolers, 201, 203–204

enantiomers of, 195 gender effects and, 196, 198

indications for, 9-10

mechanism of action of, 3–5, 192–193 mother-child interactions and, 199 for obsessive compulsive disorder, 902

for obsessive compulsive disorder, 90 patients refractory to treatment with, strategies for, 215–216 peer relationships and, 199–200

pharmacokinetics of, 194 pharmacology of, 3-9, 192-195

plasma level of, 7–8 preparations of, 213–214

rebound and, 212 seizure disorders and, 210 therapeutic actions of, 10–12

therapeutic monitoring of, 16-20 tic disorders and, 208

Stimulants (Continued) toxicology of, 8-9 Stroke. See also Cerebrovascular disease. amnesia and, 419-420 aphasia and, 416, 417, 418 behavioral neurology and, 415-423 dementia and, 421-422 depression and, 422 limb apraxia and, 420 neglect syndrome and, 416-417, 419 nonhemiplegic cortical behavioral syndromes and, 421 visual syndromes and, 420-421 Structured Interview for DSM-III Personality Disorders (SIDP), in obsessive compulsive disorder, 807-Subacute sclerosing panencephalitis, 328 Subcaudate tractotomy, for obsessive compulsive disorder, 925 Substance abuse. See also specific substance. arson and, 631 criminal behavior and, 605-619 causality and, 612 demographics and, 613-616 forensic psychiatric evaluation in, 617-619 morbidity and mortality in, 612-613 pharmacologic treatment of, 179-188 violence and, 557, 605-619 sexual, 705 Suicide, risk of, after psychosurgery for obsessive compulsive disorder, 933 Sulpuride, for tic disorders, 121-122 Supersensitivity psychosis, as medication side effect, in schizophrenia, 142 neuroleptic withdrawal and, 265-266 Supranuclear palsy, progressive, 325 Surgery, epilepsy, complex partial seizures and, 380 in obsessive compulsive disorder treatment, 818, 921-935 Symmetry, need for, obsessive compulsive disorder and, 751 Systemic lupus erythematosus (SLE), with central nervous system involvement, 439-451 diagnosis of, 446-449 prevalence of, 442 primary pathogenesis of, 443-445 prognosis of, 449-450 spectrum of, 442-443 treatment of, 450-451 diagnosis of, 439-441 neuropsychiatric dysfunction as pre-

senting clinical manifestation of,

nonfocal cerebral dysfunction in, 445-

446

nonlupus causes of neuropsychiatric disease in, 445

Tardive akathisia, 262, 493-494 Tardive dyskinesia, classic, 492-493 clinical features of, 492-494 differential diagnosis of, 495-496 epidemiology of, 492 as medication side effect, 492-498 neuroleptics and, 259-262 in schizophrenia, 141-142 pathophysiology of, 494-495 risk factors for, 492 treatment of, 496-498 Tardive dystonia, 262, 493 Tardive mvoclonus, 494 Tardive oculogyric crisis, 494 Tardive parkinsonism, 494 Tardive tics, 494 Tardive Tourette's syndrome, neurolepticinduced, 262, 494 Temporal lobe, diseases of, 319-321 tumors of, 326 Terrorism, firesetting in, 629 Testimony, 533-535 Thallium exposure, 331 Thioridazine. See also Neuroleptics. stimulants versus, for ADHD, 23 Thought disorders, arson associated with, 630 Thoughts, intrusive, behavioral patterns associated with, 837-839 Thyroid disease, 328-329 Tic disorders. See also Tourette's syndrome. assessment of, 115-118 associated conditions with, 112-115 chronic motor tics, behavior therapy for, 854-856 clinical phenomena of, 110-112 cocaine-related, 505 neuroleptic-induced, 259, 494 obsessive compulsive symptoms and, pharmacotherapy of, 109-127 in ADHD, 122-123 in anxiety, 125 clonidine in, 120-121 in depression, 125 discontinuation of, 126 haloperidol in, 119-120 medication combinations in, 125-126 medication selection for, 122 in OCD, 123-125 phenothiazines in, 121 pimozide in, 120 sulpuride in, 121-122 sleep disorders associated with, 176-177 stimulants in, 208

treatment approaches to, 118-119 Tobacco-alcohol amblyopia, 365-366 Tourette's syndrome, 325-326. See also Tic disorders anxiety with, 125

attention deficit hyperactivity disorder with, 122-123

behavior therapy for, 854-856 depression with, 125

epidemiology of, 849-850

genetics of, obsessive compulsive disorder and, 759-764, 850-851

neuropathology of, 852-853 OCD and, 853-854

obsessive compulsive disorder and, 123-125

clinical aspects of, 849-857 familial/genetic relationship between,

neuropathology of, 853-854

treatment response of, 854-857 pharmacotherapy of, 109-127

response to, 854

phenomenology of, 851-852 sleep disorders associated with, 176-177 stimulants in, 208

tardive, neuroleptic-induced, 262, 494 Toxicology, stimulant, 8-9

Toxins, psychiatric disorders due to, 331 Trauma. See also Head injuries.

increased incidence of, in alcoholism,

Trial, fitness for, major affective disorders and, 572

Trichotillomania, 777-788

associated disorders with, 782 classification of, 786-787

clinical presentation of, 780-782

early-onset, 779-780

adolescent onset versus, 787-788 family history in, 782-783 long-term follow-up of, 783, 785 NIMH patient sample with, 778-779 as obsessive compulsive "spectrum"

disorder, 785-786 in older children, adolescents, and adults, 780-785

treatment of, 783, 784

Tricyclic antidepressants, 223-237. See also Antidepressants.

alternatives to, 237

for anorexia nervosa, 155-156

for anxiety disorders, pediatric, 50-54 for obsessive compulsive disorder, 895-

augmentation strategies using, 909 pharmacokinetics of, 223-226

in children and adolescents, 226-232,

in prepubertal major depression, 31-36

adolescent, 32

cardiovascular precautions with, 34-

efficacy of, 32-34

lithium augmentation of, 36 pharmacokinetics of, 34

side effects of, pediatric, 231-232

stimulants versus, for ADHD, 21-23 Tryptophan, for obsessive compulsive

disorder, 901 augmentation strategies using, 908

Tumors, psychiatric manifestations of, 326-327

Twin studies, of Tourette's syndrome and obsessive compulsive disorder, 850-

Vagrants, firesetting by, 629 Vandalism, fires in, 629 Vanity, firesetting and, 629 Violence. See also Crime.

on admission, schizophrenia and, 581-

evaluation and management of, 553-566 homicidal behavior. See Homicide. among inpatients, schizophrenia and, 582-584

patient history of, 554

prediction of, legal issues and, 565-566 prevention of, 557-558

schizophrenic psychopathology and, 578-580

sexual, 703-714. See also Sexual violence. Violent patient. See also Offender.

behavioral treatment programs for, 565 chief complaint of, 554

evaluation of, 553-557 laboratory testing of, 555

management of, 558-566 medical history of, 554-555

medication for, emergency, 558-560 long-term, 560-562

physical examination of, 555 psychiatric disorders in, 556

safety and, 558

seclusion and restraint of, contraindications to, 563-564

indications for, 562-563

physician and nurse reviews and, 564 release from, 564-565 room for, 564

substance abuse in, 557, 605-619

Visual hallucinations, 352-353. See also Hallucinations.

Visual syndromes, stroke and, 420-421 Visuoconstructive functions,

neuropsychological assessment of,

Visuoperceptive functions, neuropsychological assessment of, 293

Visuospatial functions, neuropsychological assessment of, 293 in obsessive compulsive disorder, 831–

832

Vitamin B<sub>12</sub> deficiency, 330

Vitamin deficiencies, psychiatric manifestations of, 330 alcoholism and, 366

Vocational services, schizophrenia and, 144

Vomiting, neuroleptic withdrawal and, 265

Welfare fraud, arson and, 626-627

Wernicke-Korsakoff syndrome, 364–365 Wilson's disease, 324–325 Withdrawal, alcohol, 360, 362–363 cocaine, 183–184 neuroleptic, 265–266 Women, firesetting by, 635 Would-be hero, firesetting by, 629

<sup>133</sup>Xe-SPECT, for cerebral blood flow, in obsessive compulsive disorder, 874– 875

Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), administration of, 864–866 construction of, 864 psychometric properties of, 866–867 Yohimbine, for obsessive compulsive disorder, 901

